Highlights
• IXICO wins a global Phase 3 Huntington's disease trial contract with an unnamed international biotechnology company.
• The contract is worth £2.7m in Revenue to IXICO, recognised over the next six years.
• It is the company's second Phase 3 Huntington's disease award in the past 12 months.
• The win follows two Alzheimer's disease contracts worth about £1.5m combined, announced on 22 October 2026.
IXICO (LSE:IXI), the AI-driven neuroimaging and biomarker analytics specialist, opened the week on 2 November 2026 with news of a global Phase 3 clinical trial contract in Huntington's disease, worth £2.7m in revenue over the next six years. The client is an international biotechnology company, which was not named, and the award lands less than a fortnight after the company reported a 28% jump in annual revenue.
IXICO contract win: what was announced
The new mandate covers a global Phase 3 trial in Huntington's disease (HD), where IXICO will apply its AI-driven neuroimaging and biomarker analytics platform. It is the second Phase 3 HD contract IXICO has been awarded in the past 12 months.
On a straight-line basis, £2.7m across six years works out at about £0.45m a year; the company did not set out how revenue will be phased.
Chief executive Bram Goorden said the contract reflects IXICO's position in the neurodegenerative disease field. He added that it demonstrates progress in strengthening the order book "through an increasing contribution from later-stage clinical trials, providing long-term revenue visibility and supporting our growth ambitions."
A run of contract wins in October and November
The HD award follows two Alzheimer's disease contracts announced on 22 October with a combined value of about £1.5m. One is a new contract with a biotechnology company to manage and analyse neuroimaging data for a Phase 2b trial, with revenue expected over roughly three years. The other extends work for an existing international life sciences and diagnostics company, using IXICO's IXI neuroimaging platform to support validation and regulatory approval of a blood-based biomarker for Alzheimer's diagnosis.
The company described the October contracts as a continuation of its revenue growth momentum and order book expansion. Goorden said at the time: "Securing these two contracts again demonstrates the breadth of IXICO's capabilities in Alzheimer's disease."
Financial context from the FY26 trading update
On 20 October, IXICO said revenue for the year to 30 September 2026 was £8.3m, up 28% from £6.5m and ahead of upgraded guidance of £8.0m. The order book stood at £16.0m at the year end, against £13.8m a year earlier.
Cash rose to £10.4m from £3.5m, reflecting a £9.4m net Capital raise completed in April 2026. The loss before interest, tax, Depreciation and Amortisation is expected to come in better than guidance of a £1.7m loss. Measured against the year-end order book, the new contract equals about 17%.
Risks and open points
Revenue from trial services is tied to the progress of each client's study, and a six-year contract runs over a long horizon in which timelines can shift. The client and the investigational therapy were not named, and the announcement did not give a revenue profile by year.
IXICO also continues to invest for growth, so the balance between contract wins and operating losses remains a point for investors in AIM healthcare stocks to track.
What investors may watch next
The next scheduled marker is the audited FY26 results, due in December 2026. Any order book update issued after the October and November wins will show how far these contracts have moved the total. IXICO, quoted on AIM, also presented new Huntington's disease study findings on 29 October, a reminder of the scientific work behind its pitch to UK small-cap shares followers. Further contract announcements, and the share of revenue coming from later-stage trials, are the other figures to follow on the London Stock Exchange.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...